Two COVID-19 vaccines developed by AstraZeneca and J&J  have developed rare blood clot events during inoculation program after these were approved for use. AstraZeneca vaccine that has been widely approved across many nations has been halted by more than a dozen countries, mostly in Europe and dropped out completely by Denmark, the first country in EU to do so.

In contrast, the  J&J vaccine which is approved in limited nations and is in process of getting approval in many nations, have recently developed rare blood clot  among six women ages 18 to 48 in US, with symptoms developing six to 13 days after they received the shot. This prompted FDA to advises states to pause use of J&J Covid vaccine for “out of an abundance of caution.” This will surely impact the global rollover these vaccines.

European Union Commission has decided not to renew COVID-19 vaccine contracts next year with AstraZeneca and Johnson & Johnson (J&J)